Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

MK-8776 and Olaparib Combination Acts Synergistically in Hepatocellular Carcinoma Cells, Demonstrating Lack of Adverse Effects on Liver Tissues in Ovarian Cancer PDX Model

W. Bębenek, A. Gajek, A. Marczak, J. Malý, J. Smejkal, M. Statkiewicz, N. Rusetska, M. Bryś, A. Rogalska

. 2025 ; 26 (2) : . [pub] 20250120

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010221

Grantová podpora
Sonata Bis 2019/34/E/NZ7/00056 National Science Centre, Poland

Hepatocellular carcinoma (HCC) cells critically depend on PARP1 and CHK1 activation for survival. Combining the PARP inhibitor (PARPi) olaparib with a CHK1 inhibitor (MK-8776, CHK1i) produced a synergistic effect, reducing cell viability and inducing marked oxidative stress and DNA damage, particularly in the HepG2 cells. This dual treatment significantly increased apoptosis markers, including γH2AX and caspase-3/7 activity. Both HCC cell lines exhibited heightened sensitivity to the combined treatment. The effect of drugs on the expression of proliferation markers in an olaparib-resistant patient-derived xenograft (PDX) model of ovarian cancer was also investigated. Ovarian tumors displayed reduced tissue growth, as reflected by a drop in proliferation marker Ki-67 levels in response to PARPi combined with CHK1i. No changes were observed in corresponding liver tissues using Ki-67 and pCHK staining, which indicates the absence of metastases and a hepatotoxic effect. Thus, our results indicate that the dual inhibition of PARP and CHK1 may prove to be a promising therapeutic approach in the treatment of primary HCC as well as OC tumors without the risk of liver metastases, especially in patients with olaparib-resistant tumor profiles.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010221
003      
CZ-PrNML
005      
20250429135220.0
007      
ta
008      
250415s2025 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms26020834 $2 doi
035    __
$a (PubMed)39859548
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Bębenek, Wiktoria $u Department of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland $u Doctoral School of Exact and Natural Sciences, University of Lodz, Jana Matejki 21/23, 90-237 Lodz, Poland $1 https://orcid.org/0009000197058780
245    10
$a MK-8776 and Olaparib Combination Acts Synergistically in Hepatocellular Carcinoma Cells, Demonstrating Lack of Adverse Effects on Liver Tissues in Ovarian Cancer PDX Model / $c W. Bębenek, A. Gajek, A. Marczak, J. Malý, J. Smejkal, M. Statkiewicz, N. Rusetska, M. Bryś, A. Rogalska
520    9_
$a Hepatocellular carcinoma (HCC) cells critically depend on PARP1 and CHK1 activation for survival. Combining the PARP inhibitor (PARPi) olaparib with a CHK1 inhibitor (MK-8776, CHK1i) produced a synergistic effect, reducing cell viability and inducing marked oxidative stress and DNA damage, particularly in the HepG2 cells. This dual treatment significantly increased apoptosis markers, including γH2AX and caspase-3/7 activity. Both HCC cell lines exhibited heightened sensitivity to the combined treatment. The effect of drugs on the expression of proliferation markers in an olaparib-resistant patient-derived xenograft (PDX) model of ovarian cancer was also investigated. Ovarian tumors displayed reduced tissue growth, as reflected by a drop in proliferation marker Ki-67 levels in response to PARPi combined with CHK1i. No changes were observed in corresponding liver tissues using Ki-67 and pCHK staining, which indicates the absence of metastases and a hepatotoxic effect. Thus, our results indicate that the dual inhibition of PARP and CHK1 may prove to be a promising therapeutic approach in the treatment of primary HCC as well as OC tumors without the risk of liver metastases, especially in patients with olaparib-resistant tumor profiles.
650    12
$a ftalaziny $x farmakologie $7 D010793
650    12
$a piperaziny $x farmakologie $7 D010879
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    12
$a hepatocelulární karcinom $x farmakoterapie $x patologie $x metabolismus $7 D006528
650    12
$a nádory jater $x farmakoterapie $x patologie $x metabolismus $7 D008113
650    _2
$a zvířata $7 D000818
650    12
$a synergismus léků $7 D004357
650    12
$a nádory vaječníků $x farmakoterapie $x patologie $x metabolismus $7 D010051
650    _2
$a myši $7 D051379
650    12
$a xenogenní modely - testy protinádorové aktivity $7 D023041
650    _2
$a PARP inhibitory $x farmakologie $x terapeutické užití $7 D000067856
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a pyrazoly $x farmakologie $7 D011720
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a checkpoint kinasa 1 $x metabolismus $x antagonisté a inhibitory $7 D000071877
650    _2
$a poškození DNA $x účinky léků $7 D004249
650    _2
$a buňky Hep G2 $7 D056945
650    _2
$a játra $x účinky léků $x patologie $x metabolismus $7 D008099
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a protokoly protinádorové kombinované chemoterapie $x farmakologie $x terapeutické užití $x škodlivé účinky $7 D000971
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a pyrimidiny $7 D011743
655    _2
$a časopisecké články $7 D016428
700    1_
$a Gajek, Arkadiusz $u Department of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland $1 https://orcid.org/000000033475441X
700    1_
$a Marczak, Agnieszka $u Department of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland $1 https://orcid.org/0000000334399032
700    1_
$a Malý, Jan $u Faculty of Science, University of Jan Evangelista Purkyně in Ústí nad Labem, 400 96 Ustí nad Labem, Czech Republic
700    1_
$a Smejkal, Jiří $u Faculty of Science, University of Jan Evangelista Purkyně in Ústí nad Labem, 400 96 Ustí nad Labem, Czech Republic
700    1_
$a Statkiewicz, Małgorzata $u Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 5 Roentgena Street, 02-781 Warsaw, Poland
700    1_
$a Rusetska, Natalia $u Department of Experimental Immunology, Maria Sklodowska-Curie National Research Institute of Oncology, 5 Roentgena Street, 02-781 Warsaw, Poland
700    1_
$a Bryś, Magdalena $u Department of Cytobiochemistry, Institute of Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland $1 https://orcid.org/0000000277255429
700    1_
$a Rogalska, Aneta $u Department of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland $1 https://orcid.org/0000000241701693
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 26, č. 2 (2025)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39859548 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135215 $b ABA008
999    __
$a ok $b bmc $g 2311534 $s 1247302
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 26 $c 2 $e 20250120 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a Sonata Bis 2019/34/E/NZ7/00056 $p National Science Centre, Poland
LZP    __
$a Pubmed-20250415
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace